EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Effectiveness of ensitrelvir for cough caused by COVID-19 Omicron variant in patients with asthma

Naoyuki Miyashita iD, Nobuyuki Horita, Yasushi Nakamori, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Tomoki Ito

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.03407-24 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Naoyuki Miyashita und 6 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, Hirakata, Jap…. Hauptthemen laut MEDLINE: Asthma, Cough, COVID-19, SARS-CoV-2. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the post-acute coronavirus disease 2019 (COVID-19) period, patients with asthma had a significantly higher risk of cough than patients without a history of asthma. In particular, cases with persistent cough were increased during the Omicron variant epidemic. In this study, we evaluated the efficacy of ensitrelvir for the treatment of cough associated with COVID-19 Omicron variants in patients with asthma. This follows the Strengthening the Reporting of Observational Studies in Epidemiology statement. A total of 223 patients were registered in this study: 121 patients chose ensitrelvir, and 102 patients chose symptomatic treatment. Cough severity, frequency, and cough-specific quality of life were evaluated using the Japanese version of the Leicester Cough Questionnaire (J-LCQ). J-LCQ documented at baseline on days 4, 7, and 14 for all patients showed a steady improvement over time in both groups. In the mixed model for repeated measures model, which accounts for repeated measurements, the change in J-LCQ score from baseline was 2.1 points higher in the ensitrelvir group ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaCoughCOVID-19SARS-CoV-2COVID-19 Drug TreatmentAntiviral AgentsHumansMaleFemaleMiddle AgedQuality of LifeAgedAdultTreatment OutcomeSurveys and QuestionnairesSeverity of Illness IndexIndazolesTriazinesTriazoles

Stichwörter der Autor:innen

COVID-19Omicron variantSARS-CoV-2cough symptomensitrelvir

Substanzen

Antiviral AgentsensitrelvirIndazolesTriazinesTriazoles

Autor:innen und Institutionen

  • First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, Hirakata, Japan.
  • Chemotherapy Center, Yokohama City University Hospital, Yokohama, Japan.
  • Department of Emergency Medicine, Kansai Medical University Medical Center, Hirakata, Japan.

ORCID-Profile: Naoyuki Miyashita

Zitieren

APA

Miyashita, N., Horita, N., Nakamori, Y., Ogata, M., Fukuda, N., Yamura, A., & Ito, T. (2025). Effectiveness of ensitrelvir for cough caused by COVID-19 Omicron variant in patients with asthma. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03407-24

Vancouver

Miyashita N, Horita N, Nakamori Y, Ogata M, Fukuda N, Yamura A, et al. Effectiveness of ensitrelvir for cough caused by COVID-19 Omicron variant in patients with asthma. Microbiology Spectrum. 2025. doi:10.1128/spectrum.03407-24

BibTeX
@article{Miyashita2025,
  author = {Miyashita, Naoyuki and Horita, Nobuyuki and Nakamori, Yasushi and Ogata, Makoto and Fukuda, Naoki and Yamura, Akihisa and Ito, Tomoki},
  title = {Effectiveness of ensitrelvir for cough caused by COVID-19 Omicron variant in patients with asthma},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.03407-24}
}
Kostenlos starten →